Avalo Therapeutics CMO H. Jeffrey Wilkins resigns; effective date TBD

Avalo Therapeutics, Inc.

Dr. Wilkins resigns as Chief Medical Officer effective upon a date to be agreed upon.
He will assist in orderly transition of duties through the effective date.
No replacement named in the filing.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

H. Jeffrey Wilkins

Chief Medical Officer

AVTX · Avalo Therapeutics, Inc.

Filed: February 8, 2022, 6:59 PM ET

On February 2, 2022, H. Jeffrey Wilkins resigned as Chief Medical Officer of Avalo Therapeutics, Inc., to be effective upon a date to be agreed upon.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

H. Jeffrey Wilkins resigned as Chief Medical Officer at Avalo Therapeutics, Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On February 2, 2022, H. Jeffrey Wilkins resigned as Chief Medical Officer of Avalo Therapeutics, Inc., to be effective upon a date to be agreed upon.

View on SEC.gov

Avalo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-002018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.